Closure of the tipranavir trials SPRING and TICINO
- Details
- Category: Boehringer Ingelheim
After careful consideration of the feasibility of meeting the enrolment targets for the SPRING (Safety, efficacy and pharmacokinetics of tipranavir boosted with low dose ritonavir (500mg/200mg) twice daily in 400 racially and gender diverse HIV-positive treatment-experienced population) and TICINO (safety and efficacy of tipranavir/ritonavir in treatment-experienced patients also infected with the hepatitis B or hepatitis C viruses) trials, Boehringer Ingelheim has terminated both studies.
Novo Nordisk employee suspended after being charged with insider trading
- Details
- Category: Novo Nordisk
Novo Nordisk has suspended one of its employees after the employee yesterday was charged by the Danish Public Prosecutor for Serious Economic Crime with unlawful insider trading in the company's shares.
First interleukin-6 inhibitor (IL-6) to offer new therapeutic option for rheumatoid arthritis
- Details
- Category: Roche
Roche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of Actemra (tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).
Significant blood pressure reductions seen with Exforge across difficult-to-treat groups
- Details
- Category: Novartis
New data show that Exforge, a single-pill combination of the world's leading high blood pressure medicines Diovan® (valsartan) and amlodipine, gets nearly twice as many patients with high baseline blood pressure to a healthier blood pressure goal compared to amlodipine alone[1].
GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and the Harvard Stem Cell Institute (HSCI) announced that they have entered into a five-year, $25 million-plus collaborative agreement to build a unique alliance in stem cell science, leading to the development of new medicines.
Nexavar Approved for Treatment of Liver Cancer in China
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar® (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer.
Nexavar Study Demonstrates Significant Improvement in Overall Survival
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that The New England Journal of Medicine published landmark results of a Nexavar study in liver cancer. The data of the Phase III trial showed that Nexavar® (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo.
More Pharma News ...
- Pfizer Reports Second-Quarter 2008 Results
- GlaxoSmithKline teams up with academia to develop new medicines of value
- Novartis gains momentum with strong performance in first half of 2008
- Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter
- Boehringer Ingelheim FENS Award for exceptional research in neuroscience
- Novartis completes acquisition of 25% stake in Alcon from Nestlé
- Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows